Rapamycin (Sirolimus) Pregnancy & Lactation Safety

How Sirolimus Works: The mTOR Pathway and Why It Matters for Reproduction

Sirolimus blocks the mechanistic target of rapamycin complex 1 (mTORC1) by binding the intracellular protein FKBP12, forming a complex that directly inhibits mTOR kinase activity [1]. MTORC1 coordinates cell growth, protein synthesis, and autophagy in nearly every mammalian tissue. That breadth is clinically useful for immunosuppression and, experimentally, for slowing aging, and it is also what makes sirolimus biologically dangerous during pregnancy.

mTOR in Placental Development

The placenta depends on mTOR signaling at multiple stages. Trophoblast invasion of the uterine decidua, spiral artery remodeling, and nutrient transport across the syncytiotrophoblast all require intact mTORC1 activity [2]. Studies in human placental explants confirm that acute mTOR inhibition with rapamycin at nanomolar concentrations reduces amino acid transport by 30 to 60%, a magnitude consistent with fetal growth restriction [3].

mTOR in Gametogenesis and Early Embryo

Oocyte maturation and the pre-implantation embryo both require mTORC1. Rapamycin exposure during murine folliculogenesis shortens reproductive lifespan and reduces litter size in a dose-dependent fashion [4]. These animal findings directly inform the FDA label's warning that sirolimus may impair fertility in women of reproductive potential [5].

The FKBP12 Distribution Problem

FKBP12, the intracellular receptor through which sirolimus acts, is expressed in fetal brain, heart, and kidney tissue beginning in the first trimester [1]. Because sirolimus is highly lipophilic (log P ~4.3) and crosses cell membranes readily, fetal organ exposure begins as soon as the drug crosses the placental barrier, which animal data confirm it does [5].

FDA Labeling and Regulatory Classification

The current FDA prescribing information for Rapamune (Pfizer) carries an explicit contraindication for use in pregnancy based on findings from multiple animal species [5]. Under the Pregnancy and Lactation Labeling Rule (PLLR), the label states that sirolimus caused embryo-fetal toxicity in rats at a dose approximately 0.2 times the human recommended daily dose of 2 mg/day on a body-surface-area basis [5].

Animal Toxicology Summary

In rat studies, sirolimus at 0.1 mg/kg/day (approximately 0.2× the human recommended dose) produced increased embryo-fetal mortality and reduced fetal weights. Rabbit studies at comparable exposures showed similar findings [5]. These are not high-dose artifact results, they occur at sub-therapeutic human exposures, which removes the usual reassurance that animal data are only relevant at supratherapeutic doses.

No Adequate Human Controlled Data

The FDA label explicitly states: "There are no adequate and well-controlled studies in pregnant women." [5] The available human data come entirely from transplant registries and case series, not from prospective controlled trials. The National Transplantation Pregnancy Registry (NTPR) has collected outcomes in solid-organ transplant recipients exposed to sirolimus, but sample sizes for sirolimus-specific exposure are small and confounded by polypharmacy with calcineurin inhibitors [6].

Contraception Requirements

The FDA label requires that women of reproductive potential use effective contraception before starting sirolimus, during the entire course of therapy, and for 12 weeks after the last dose [5]. This 12-week window reflects approximately 4 to 5 half-lives to ensure near-complete elimination, given sirolimus's mean half-life of 62 hours (range 46 to 78 hours) in healthy adults [5].

Human Pregnancy Outcomes: Transplant Registry Data

Most human data on sirolimus in pregnancy come from solid-organ transplant recipients, where the drug is used at daily doses of 2 to 5 mg targeting whole-blood trough levels of 4 to 12 ng/mL [6].

NTPR Findings

The National Transplantation Pregnancy Registry has tracked pregnancy outcomes in transplant recipients since 1991. In its published analyses, sirolimus-exposed pregnancies (N reported in various cohorts ranging from single digits to approximately 50 cases) showed rates of preterm birth exceeding 40%, fetal growth restriction in roughly 30% of livebirths, and a small number of structural anomalies [6]. The NTPR authors caution that attribution to sirolimus specifically is difficult because all patients also received calcineurin inhibitors, mycophenolate, or corticosteroids [6].

Recommended Switch Before Conception

The American Society of Transplantation and most nephrology guidelines recommend converting patients from sirolimus to a calcineurin inhibitor (tacrolimus or cyclosporine) at least 6 weeks before a planned conception, given the better-characterized, though still imperfect, safety profile of calcineurin inhibitors in pregnancy [7]. Mycophenolate is separately contraindicated in pregnancy and should also be discontinued.

Case Reports of Inadvertent Exposure

Several published case reports describe inadvertent first-trimester sirolimus exposure in transplant recipients who became pregnant unexpectedly. Outcomes varied from normal neonates (after early drug discontinuation) to preterm delivery with low birth weight [8]. One case series from a French transplant center reported that all five sirolimus-exposed pregnancies resulted in live births after drug conversion at 6 to 10 weeks gestation, but four of five neonates required neonatal intensive care admission [8].

Lactation: Breast-Milk Transfer Data

Documented Transfer in Case Reports

Sirolimus transfer into human breast milk is confirmed in at least one published case report. A lactating kidney-transplant recipient taking sirolimus 2 mg/day had measurable sirolimus concentrations in breast milk at approximately 6.3 ng/mL, yielding a milk-to-plasma ratio of roughly 0.13 and an estimated infant daily dose of approximately 0.94 mcg/kg/day [9]. That estimated infant dose represents less than 1% of the weight-adjusted maternal dose, which is generally below the threshold of clinical concern for most drugs, but sirolimus is not most drugs.

Why Low Transfer Still Matters

The infant gut absorbs a fraction of the milk-delivered sirolimus dose, and bioavailability in neonates is poorly characterized. Because mTOR signaling governs neonatal brain growth, gut maturation, and immune development, even low-level chronic exposure during the neonatal period carries theoretical risk [2]. No long-term infant follow-up data exist for sirolimus-exposed breastfed infants.

FDA and Guideline Recommendation

The FDA label states that it is not known whether sirolimus is excreted in human milk, and it recommends that women not breastfeed during sirolimus therapy and for 12 weeks after the last dose [5]. This recommendation is conservative relative to the single published pharmacokinetic case report, but it reflects the absence of infant safety data rather than confirmed harm at measured doses.

Sirolimus for Off-Label Longevity Use: A Distinct Risk Profile

The PEARL trial (Aging Cell, 2024; N=159 healthy adults aged 50 to 85) examined self-reported health outcomes and immune markers in participants taking low-dose sirolimus (1 mg/day or 5 mg/week) over 16 weeks [10]. PEARL enrolled postmenopausal women and older men; no reproductive-age women were included in the active-treatment cohort [10]. The trial's findings on immune function and self-reported health cannot be extrapolated to pregnant or lactating individuals.

No Safe Dose Has Been Identified in Pregnancy

Off-label longevity protocols typically use 1 to 6 mg once weekly, producing peak whole-blood concentrations of 5 to 15 ng/mL followed by a trough near or below 1 ng/mL by day 7 [10]. Whether this pulsatile exposure is safer than daily dosing in pregnancy is entirely unknown. Animal embryotoxicity occurred at continuous low-dose exposure, and no animal or human data characterize intermittent weekly dosing in pregnancy [5].

Decision Framework: Reproductive-Age Women Considering Longevity Rapamycin

Clinicians prescribing sirolimus off-label for longevity to women under age 55 should apply the following sequential checks before initiating therapy:

1. Confirm the patient is postmenopausal (FSH above 40 IU/L on two occasions at least 6 weeks apart) or has undergone surgical menopause.
2. If premenopausal or perimenopausal, document a negative urine pregnancy test within 7 days of the first dose.
3. Confirm the patient is using at least one highly effective contraceptive method (IUD, implant, sterilization, or combined hormonal contraception).
4. Counsel that oral contraceptive pill efficacy may be altered by sirolimus, which induces CYP3A4 and P-glycoprotein at higher doses, necessitating a non-hormonal backup or IUD [5].
5. Repeat pregnancy testing every 3 months while the patient remains on therapy.
6. Document the 12-week post-discontinuation contraception requirement at every annual review.

This framework is not derived from a published guideline; it reflects synthesis of the FDA label's contraception requirements and standard reproductive-safety practice for Category X / PLLR contraindicated drugs.

Drug Interactions Relevant to Contraception and Pregnancy Planning

Sirolimus is metabolized by CYP3A4 and transported by P-glycoprotein [5]. Co-administration with strong CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin) substantially raises sirolimus whole-blood concentrations, increasing toxicity risk if a patient inadvertently continues therapy into pregnancy. Strong CYP3A4 inducers (rifampin, rifabutin, St. John's Wort) reduce sirolimus concentrations and may lower contraceptive hormone levels when combined with oral hormonal contraceptives [5].

Calcineurin Inhibitor Co-Administration

In transplant patients, sirolimus is often co-administered with cyclosporine. Cyclosporine significantly increases sirolimus AUC, requiring dose adjustment [5]. This combination also increases the risk of thrombotic microangiopathy, a condition already associated with pregnancy. Women on combined cyclosporine-sirolimus therapy who become pregnant carry compounded fetal and maternal risk.

Fertility Impairment: Pre-Conception Counseling Points

Beyond teratogenicity, sirolimus may impair fertility before conception occurs. Animal studies show reduced sperm motility and count in male rats exposed to sirolimus [5]. In women, mTOR inhibition disrupts folliculogenesis, as demonstrated in mouse models where chronic rapamycin treatment accelerated primordial follicle depletion [4]. One small human case series in female renal transplant recipients found menstrual irregularity in 3 of 8 patients switched to sirolimus from calcineurin inhibitors, normalizing after drug discontinuation [11].

The FDA label states: "Sirolimus may be associated with impaired fertility in females and males of reproductive potential." [5] Patients who wish to conceive should discontinue sirolimus and allow at least 12 weeks for washout before attempting conception, and they should undergo fertility evaluation if conception has not occurred within 6 months of drug discontinuation.

Monitoring Recommendations for Accidental Exposure

If a patient becomes pregnant while taking sirolimus, the following steps reflect standard clinical practice based on transplant society guidance:

• Discontinue sirolimus immediately upon confirmed pregnancy.
• Obtain whole-blood sirolimus trough level to document exposure magnitude.
• Refer to maternal-fetal medicine for high-risk obstetric surveillance.
• Offer detailed fetal anatomy ultrasound at 18 to 20 weeks.
• Serial growth ultrasounds every 4 weeks from 24 weeks gestation given the risk of fetal growth restriction documented in registry data [6].
• Neonatal team notification before delivery.
• Report the exposure to the National Transplantation Pregnancy Registry (transplant patients) or, for longevity-use exposures, to the FDA MedWatch program at fda.gov.